Argenx price target raised to $475 from $465 at Piper Sandler

Piper Sandler analyst Allison Bratzel raised the firm’s price target on Argenx to $475 from $465 and keeps an Overweight rating on the shares. The firm increased near-term Vyvgart estimates following new neurologist surveys that it views as "quite bullish." The two major takeaways on key 2023 growth drivers are the shift toward earlier-line Vyvgart adoption is well underway, and projected uptake of the subQ format is "impressive" and indicates more than a two-fold increase in potential patient share for Argenx’s overall generalized myasthenia gravis franchise within six months, the analyst tells investors in a research note.